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The Coordination, Rationalization, and Integration of antiMALarial drug Discovery & Development Initiatives
(CRIMALDDI) Consortium, funded by the EU Framework Seven Programme, has attempted, through a series of
interactive and facilitated workshops, to develop priorities for research to expedite the discovery of new anti-
malarials. This paper outlines the recommendations for the development of enabling technologies and the identifi-
cation of novel targets.
Screening systems must be robust, validated, reproducible, and represent human malaria. They also need to be
cost-effective. While such systems exist to screen for activity against blood stage Plasmodium falciparum, they are
lacking for other Plasmodium spp. and other stages of the parasite’s life cycle. Priority needs to be given to develop-
ing high-throughput screens that can identify activity against the liver and sexual stages. This in turn requires other
enabling technologies to be developed to allow the study of these stages and to allow for the culture of liver cells
and the parasite at all stages of its life cycle.
As these enabling technologies become available, they will allow novel drug targets to be studied. Currently anti-
malarials are mostly targeting the asexual blood stage of the parasite’s life cycle. There are many other attractive tar-
gets that need to be investigated. The liver stages and the sexual stages will become more important as malaria
control moves towards malaria elimination. Sexual development is a process offering multiple targets, even though
the mechanisms of differentiation are still not fully understood. However, designing a drug whose effect is not cura-
tive but would be used in asymptomatic patients is difficult given current safety thresholds. Compounds active
against the liver schizont would have a prophylactic effect and Plasmodium vivax elimination requires effectors
against the dormant liver hypnozoites. It may be that drugs to be used in elimination campaigns will also need to
have utility in the control phase. Compounds with activity against blood stages need to be screened for activity
against other stages.
Natural products should also be a valuable source of new compounds. They often occupy non-Lipinski chemical
space and so may reveal valuable new chemotypes.
Keywords: CRIMALDDI, Malaria, Drug discovery, Research agenda, Novel targets, Enabling technologies,
PrioritizationBackground
There has been significant progress in recent years to-
wards the global goal of malaria elimination. However,
the recent reports of artemisinin resistance in Southeast
Asia have emphasized the continuing need for a wide
range of anti-malarials with novel chemical scaffolds and
modes of action. This is needed to adequately address* Correspondence: saward@liverpool.ac.uk
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reproduction in any medium, provided the orthe challenges to current drugs and extend the armoury
to those aspects that are not well served by current drugs
(especially against Plasmodium vivax malaria and trans-
mission of the disease). The ultimate goal of elimination
demands a range of new drugs must be developed quickly
to meet very different challenges compared to control.
A major challenge for successful anti-malarial drug
discovery is to quickly identify druggable targets and
leads. This requires improved methods to study the vari-
ous stages of the parasite life cycle (e, g. liver and blood
stages, sexual forms, and midgut sporozoites) so as to. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cycle stages are difficult to maintain or produce ex vivo.
Research on human malaria is hampered by techno-
logical difficulties that limit the study of parasite biology
on all malaria stages and disease pathogenesis. Special-
ized laboratories or infrastructure ‘platforms’ are thus re-
quired to provide access to particular life cycle stages,
and these methods need to be robust enough to be used
in a wide range of laboratories.
As the objective of malaria treatment moves from con-
trol to elimination [1,2], the types of drugs required are
changing. Drugs that block the infectivity of the mature
sexual form of the gametocyte [3] and or the dormant
hepatic form (hypnozoites) of P. vivax [4] will be par-
ticularly important. There will be questions about the
balance between further exploiting existing drug targets
and investing in identifying potential new ones, given
the high costs/risks associated with new drug discovery
and development. Other unanswered questions include
the best way to identify new drug targets, whether tar-
gets that are common to several life-cycle stages are bet-
ter than stage-specific targets, and how best to evaluate
and prioritize new candidate compounds.
Most currently available anti-malarials target the asexual
blood stages of the parasite’s life cycle, the only stages for
which there are robust, reproducible, and high-throughput
in vitro screening methods. However, control and elimin-
ation will require new classes of anti-malarial drugs active
against all stages of all five species of human malaria. Es-
pecially for elimination, new drugs are needed to eliminate
all malaria parasites, including the P. vivax hypnozoites to
prevent relapse, and to interfere with malaria transmission
by eliminating gametocytes. Techniques to rapidly screen
large libraries of compounds against targets at all the
stages of the parasite life cycle of all relevant Plasmodium
species are not currently available.
As described elsewhere, the Coordination, Rational-
ization, and Integration of antiMALarial drug Discovery &
Development Initiatives (CRIMALDDI) Consortium was
established to develop a prioritized set of recommenda-
tions to expedite anti-malarial drug discovery [5]. This
paper summarizes the findings of two of the Consortium’s
workshops organized to develop a set of consensus rec-
ommendations regarding enabling technologies and iden-
tifying novel targets. Full reports on the workshops can be
found on the CRIMALDDI website [6] and in the related
paper accompanying this one [7].
Developing enabling technologies
General requirements for screening methods
Screening to identify potential drug development com-
pounds active against the various stages of the Plasmo-
dium parasite life cycle can be viewed as a two-stage
process (Figure 1). Primary screens must be simpleenough to be used easily in high throughput screening
systems (HTS), whereas secondary screens can be more
complex and have only medium throughput capacity.
For blood stage Plasmodium falciparum positive HTS
hits, the current need is to filter >20,000 compounds
from HTS whose structures are in the public domain
down to <200 compounds to be considered for further
development [8].
Primary screening methods must be robust, validated,
reproducible, and represent human malaria (Table 1).
Whole cell assays are a good way of identifying chemo-
types with cellular permeability properties compatible
with accessing their targets inside the parasite in its vari-
ous stages. Screening systems must accommodate inher-
ent strategies to minimise false negative results.
Methods primarily designed to determine the mode of
action of a chemotype can be more complex and are
implemented in later stages of the drug development
process.
Additional requirements of primary screening should
include:
 Cost-effectiveness;
 Biologically appropriate, i.e. the compounds actually
kill the parasite (cidal rather than cytostatic);
 Small amount of compound needed for the screen;
 Very early exclusion of compounds cytotoxic against
the human host;
 The screening process must include reliable models
for all stages of the parasite’s life cycle;
 Candidate compounds can either be schizonticidal
plus active against another stage, or only active
against another stage. Purely schizonticidal drugs are
probably going to be of less interest as malaria
control and elimination progresses. Primary
screening must take this into account. However the
rapid spread of resistance to current first-line drugs
will require the deployment of curative agents that
will probably be schizonticidal.
Secondary screening of positive hits from a primary
screens can be more biologically informed and related to
the desired activity of the target profile being pursued.
Physiochemical and drug-like properties (including toxi-
cological profile and pharmacokinetic parameters) must
be considered since they should allow translation to
in vivo models. Secondary screening must also look for
activity against drug-resistant strains of Plasmodium and
the capacity to withstand resistance. At present, routine
screening is performed against parasite strains that obvi-
ously do not represent the strains circulating in the
population. Screens need to have early access to isolates
from patients, especially those showing resistance to im-
portant agents (such as artemisinin derivatives), and the
Figure 1 Two-stage screening process for activity against the various stages of the Plasmodium parasite life cycle.
Vial et al. Malaria Journal 2013, 12:396 Page 3 of 11
http://www.malariajournal.com/content/12/1/396culture-adapted P. falciparum and P. vivax isolates used
need to be updated regularly and promptly to reflect the
changing parasite population in the field.
All screening methods need to be validated and repro-
ducible between centres to ensure comparability of re-
sults [9].
Screening methods against blood stage parasites
The rapid identification and progression to drug devel-
opment of compounds active against acute blood stage
P. falciparum infections was made possible by the avail-
ability of an adequate range of in vitro screening assays
and animal models. In contrast, there are significant
gaps in the platform technologies necessary for investi-
gating other species of Plasmodium, particularly P. vivax
(Table 2).
Plasmodium falciparum
Along with the classic radioactive HTS screen for P. fal-
ciparum using 3H-hypoxanthine, colorimetric (pLDH,
HRPII) [10-13] or fluorescent (SybrGreen) [14] assays
have been widely used. Recently screens using transgenic
parasites (GFP, Luciferase reporter strains) have been
adapted to HTS [15-17]. At present, there is little needTable 1 Essential characteristics of screening assays for
novel compounds effective against the different stages
of malaria parasite life cycle
Robust Ensures that screens are easy to perform,
low cost, suitable for screening a large variety
of chemotypes or natural products.
Validated Ensures that the results reflect well the activity
of the compound against the targeted parasite
stage.
Reproducible Ensures that the results obtained from different
laboratories are directly comparable.
Representative of
human malaria
Ensures that the results actually reflect the
probable action of the compound(s) when
used to treat human malaria.to prioritize additional screening methods for P. falcip-
arum. However, there is the requirement to continually
upgrade the existing assays. With the emergence of artemi-
sinin resistance [18], compounds that, like artemisinins, are
active against the early ring stages of the erythrocytic cycle
or those that are active against artemisinin-resistant strains
of P. falciparum should be a priority. A low throughput
viability-based assay approach that allows discrimination
between compounds based on their anti-malarial mode-of-
action has been developed [19]. Further work is needed to
develop more novel screens or further modifications of
existing methods.
In vivo models using rodent Plasmodium species or P.
falciparum in severe combined immunodeficiency (SCID)
mice or non-human primates (NHP) are available for
pharmacological studies. Mouse models may give species
dependent screening results and so different Plasmodium
species need to be used in the initial rodent model screen-
ing of compounds. Primate models are difficult, of limited
availability, and not cost-effective.
There is a need to identify a good in vivo model for se-
vere malaria that can be used in secondary screening. To
find appropriate models, the target profile needs to be
better defined.
Plasmodium vivax
Discovery of new drugs active against P. vivax blood
stage infections is being impaired because of a lack of
HTS assays (Table 2). The development of such drugs
will be key to achieving malaria control and elimination.
The key challenge is the lack of an in vitro culture sys-
tem for growing P. vivax [20]. The availability of fresh
isolates relies on the collection of infected human blood,
which needs to be processed within six hours from col-
lection. Consequently, the laboratory facilities must be
beside the patients and in easily accessible locations. In
addition, P vivax preferentially invades reticulocytes
which are short-lived and represent only approximately
Table 2 Existing range of in vitro screening methods and in vivo models for blood stage anti-malarials
In vitro pharmacology (HTS Screens) In vivo pharmacology Human pharmacology
Plasmodium falciparum • Radioactive (3H-Hypoxanthine) Human parasite models: Human challenge
• P. falciparum in SCID mouse
• Colorimetric (pLDH, HRPII) • Aotus/Saimiri NHP
Mouse models:
• Fluorescent (Sybr Green) • Plasmodium berghei (including GFP or Luc
reporter strains)
• Transgenic parasite (GFP, Luc reporter
strains) • Plasmodium vinckei
• Plasmodium chabaudi
• Plasmodium yoelii
Plasmodium vivax Invasion assay Human parasite models
Flow cytometry (both at present only
medium throughput)
• Aotus/ Saimiri NHP
Primate models
• Plasmodium cynomolgi











• P. falciparum Mouse models Human
challenge
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ex vivo methods for isolation and cryopreservation of P.
vivax isolates and of concentrated cord blood reticulo-
cytes have been developed [21] and a short term (24
hour) invasion assay has been standardised and used for
both drug sensitivity tests and proteomics [22]. However,
the invasion assay still relies on microscopic determin-
ation of schizont maturation and reticulocytes invasion
and thus is quite laborious and requires trained personnel.
More recently, the same group [23] developed a simple,
field optimised protocol using fluorescent dyes and flow
cytometry to determine the antimalarial drug sensitivity in
freshly isolated P. vivax: this became possible mostly
because portable, low cost cytometers became available.
Flow cytometry may become a viable and practical alter-
native to microscopy, although the problem of long term
cultures of P. vivax persists and represents a key block to
future progress in a number of areas of P. vivax research.
The development of a SCID mouse model for P. vivax
could be seen as an alternative.
Virtually all P. falciparum blood stage drugs are also
active against P. vivax, but the levels of sensitivity of
each species to the drugs may differ. The workshop con-
cluded that developing primary screens that would pick
up vivax activity separately was not a priority. It should
be to develop good secondary in vivo models, particu-
larly for compounds that have a differential in vitro ac-
tivity against both species.not form
hypnozoites
• P. berghei • P. berghei









• P. cynomolgi• P. cynomolgi in
hepatocytes
from Rhesus monkeysScreening methods against liver stage parasites
Until recently, validated screening assays for liver stage
P. falciparum and P. vivax liver stages were virtually
non-existent, and much work needs to be done to de-
velop appropriate validated methods (Table 3).A major priority for the liver stages of both P. falcip-
arum and P. vivax is to develop a reproducible and ro-
bust hepatocyte culture system that is highly susceptible
to large scale invasion by malaria sporozoites. This
should ensure the complete development of the parasite
and ideally give good machinery for drug metabolism.
Another block is the lack of a robust supply of sporozo-
ites and cryogenic methods to store and transport them.
Plasmodium falciparum
Rudimentary assays already exist for liver stages that do
not form hypnozoites: P. falciparum, Plasmodium yoelii,
and Plasmodium berghei [24]. Until recently, only pri-
mary hepatocytes appeared suitable for P. falciparum
and they have very low permissivity for infection [25].
Stable and infectable hepatocyte lines and standardized
conditions for culturing hepatocytes need to be devel-
oped, because primary human liver cells are of variable
quality and lose their differentiation in culture. There is
also a priority to find ways of increasing the permissivity
of hepatocytes to infection by sporozoites. The recent
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patocytes (described below for P. vivax but also applied to
P. falciparum) is of potential value for all liver stage
models [26].Plasmodium vivax
The situation with screening for active liver stage activity
against P. vivax infections is the same as for P. falcip-
arum, with the additional challenges of (a) developing
methods to cultivate the sexual blood stage (and thus to
obtain infective sporozoites following mosquito feed)
and (b) developing appropriates tools to distinguish the
hypnozoite from the replicating schizont stage. Clearing
hypnozoites is critical for malaria elimination.
Cellular assays for the three key steps of liver-stage
biology are thus needed: hepatocyte infection, hypno-
zoite formation, and reactivation to hepatic schizonts.
Hypnozoite identification is difficult because of their
relatively small size, absence of validated biomarkers
and the low infection rate [4,24]. A small-scale liver
culture system for P. vivax, relying on cryopreserved
sporozoites has identified primaquine-sensitive small
forms [27]. Recently, schizonts and fluorescent uni-
nucleate persisting forms (displaying all the characteris-
tics of hypnozoite-forms) could be characterized for
Plasmodium cynomolgi, a simian parasite related to P.
vivax. These were observed after sporozoite infection of
Macaca fascicularis primary hepatocytes [25,28]. This
simian system provides a more reliable supply of both
parasites and primary cells as well as transgenic fluores-
cent parasites. Another recent study has reported an
in vitro model that recapitulates the entire liver stage
for both P. falciparum and P. vivax in a microscale hu-
man liver platform composed of cryopreserved, micro-
patterned human primary hepatocytes surrounded by
supportive stromal cells. This system allow the release
of infected merozoites and infection of overlaid erythro-
cytes, as well as the establishment of small forms in late
liver stages of P. vivax [26].
Biomarkers that distinguish hypnozoites from the hep-
atic schizonts are needed to speed up work on the na-
ture of dormancy. There is very little understanding of
the biology of both the liver schizont and the hypnozoite
stage of infection. The pressing question is “what is a
hypnozoite, how does it function, and how can its quies-
cent metabolism be targeted?”
The availability of robust and reliable culture models
and methods for hypnozoite identification will provide
the foundations to obtain key information on the biology
of hypnozoite and their reactivation process, paving the
way for a quantitative high-throughput liver stage screen
[29]. Once appropriate screens have been developed,
compounds will be tested first for activity against allhepatic stage in a primary screen and then secondarily
screened for hypnozoite activity.
Screening methods against sexual stages
Transmission blocking (through the sexual and mosquito-
based stages of the Plasmodium life cycle) will become
more important as malaria control moves towards malaria
elimination. It is argued that the number of parasites that
need to be killed to break the transmission cycle is orders
of magnitude less than is the case in treating infections.
Currently there is no generally accepted detailed target
profile for a new chemical entity that would act princi-
pally against the sexual stages. Such a profile needs to be
developed so that it is clear exactly which stage(s) should
be targeted (gametocytes, intermediate stages – gametes,
zygotes, ookinetes, oocysts, or finally sporozoites). Re-
cently, a comprehensive review on the next generation
of antimalarial drugs needed to control and eliminate
malaria has been published and the target candidate pro-
files (TCP) for transmission blocking agents have been
outlined [30].
Most probably conventional blood schizonticides will
block the transition from asexual to sexual stages, so
screening for drugs that block this transition is not the
first priority. However, mature gametocytes are long-
lived and even patients on treatment may continue to
transmit malaria for weeks after clearance of asexual
parasites. There is data showing that some anti-malarial
drugs can in fact induce gametocytogenesis [31]. Drugs
that will kill long-lived stage V gametocytes and/or
extra-erythrocytic parasite stages are needed to sustain
the elimination phase. Over the last few years, efforts
have been made to develop a reproducible and robust
method for producing gametocytes in vitro, and sustain
their in vitro differentiation until the long-lasting late
stage V. In addition, new assays for gametocytocidal ac-
tivity have been developed and are presently used for
large compounds screening (Table 4) [32]. These assays
fall into three major categories:
1. Measurements of parasite DNA content using
fluorescent dyes (like hydroethidine) for flow
cytometry [34]. The sensitivity is good but the
throughput is quite low. High content screening
assays for stage IV-V gametocytes are under devel-
opment [42].
2. Measurement of the metabolic/redox activity of P.
falciparum gametocytes, using the ATP
bioluminescence assay for late stage gametocytes
[36,37], the fluorimetric Alamar blue test [39,40], or
the colorimetric assay with pLDH [41]. The
advantage of all these assays is that they can be used
with common laboratory strains or even field
isolates since they do not require transgenesis.
Table 5 Existing assays for screening transmission




Male exflagellation assay [45] P. falciparum
Female activation assay (Delves,
unpublished)
P. falciparum
Standard membrane feeding assay
(SMFA) [46,47]
P. falciparum
SMFA using PbGFP CON [48] P. berghei
Anopheles stephensi
P. berghei ookinete development
assay [43]
P. berghei (transgenic)
GFP-luc sporozoites in mosquito salivary
glands [49]
P. berghei (transgenic)
Table 4 Existing in vitro assays for screening compounds
against Plasmodium falciparum gametocytes (stage I-V)





Microscopic counts of Giemsa
smear (gold standard)
Pfs16-GFP transgenic parasites [33].
Flow cytometry of hydroethidine
labelled gametocytes [34]
Stage-specific luciferase expression
in transgenic parasites [35]
ATP- bioluminescence assay for
stage IV-V gametocytes [36,37]
Three transgenic GFP lines, used
for flow cytometry assay [38]
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produce P. falciparum lines expressing GFP or GFP-
Luc reporter genes active on different stages of gam-
etocyte maturation. They have been used to identify
compounds active on early (I-II), middle (III) or late
(IV-V) stage gametocytes [35]. The GFP transgenic
lines have been used with flow cytometry [37,38].
The assays using GFP or GFP-Luc reporter genes
appear to be quite sensitive, robust, with a good sig-
nal to noise ratio.
Assays against the sporogonic stages in the mosquito
To achieve the objective of local elimination/eradication
of malaria, it is well recognized that malaria transmis-
sion through the mosquito vector must be reduced. The
standard membrane-feeding assay (SMFA) is the gold
standard assay for evaluation of any transmission-
blocking intervention, but it has a very low throughput
and is expensive.
A series of novel assays (Table 5) that can identify ac-
tivity across almost all sexual stages have been recently
described or are under development. Some of them are
still in a medium or low throughput format, but improve-
ments are expected shortly. The P. berghei ookinete devel-
opment assay is the only one adapted to HTS format [43].
The test is quite robust, and reproducible and has been
used in HTS screens of a large compound library (the Tres
Cantos Antimalarial Set (TCAMS)) [44].
To verify if stage V gametocytes are able to continue
their differentiation toward male and female gametes,
two different assays are available. The P. falciparum
exflagellation assay is limited to male gametocytes, and
although it has recently been semi-automatized by image
acquisition of motile ‘exflagellation’ events, still it is lim-
ited by the short time-window of this phenomenon [43].
The production of female gametes can be visualized by
morphology on Giemsa-stained smears. The stable ex-
pression of unique surface antigens by female gameteshas offered the possibility to develop MTS/HTS assays
of macrogametogenesis (Delves et al. unpublished).
Finally, the availability of GFP-tagged lines is trans-
forming the throughput of the SMFA assay [46], one of
the most sensitive, albeit very low throughput, assay to
evaluate transmission-blocking compounds [48]. Counting
GFP-Luc expressing salivary gland sporozoites in mos-
quito lysate is also possible, although with limited sensitiv-
ity at present and only in the P. berghei model [49].
Drugs targeted solely at the late sexual stages will need
to reside in the human body for at least five to nine days
after the appearance of symptoms. This is in order to be
present when the mature gametocytes (Stage V) start to
appear in the blood. This has significant implications for
the bioavailability and pharmacokinetic properties of drug
candidates (see “Priorities for the development of enabling
technologies”).
Priorities for the development of enabling technologies
Blood stages
 Understanding the technical problems behind the
development of a P. vivax blood stage culture
system and overcoming them.
 Development of a P. vivax blood stage rodent
model.
Liver stages
 Development of a robust hepatocyte cell system to
enable study of P. falciparum & P. vivax liver stages.
 Development of a standardised and improved
culture system for the study of P. falciparum & P.
vivax liver stages.
 Understanding of the nature and biology of
hypnozoites with the objective of identifying a
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vivax infection.
 Development of a robust and reliable supply of
falciparum and vivax sporozoites and a method for
safely transporting them between laboratories.
 Investigate the possibility of using a liver schizont
assay system as a surrogate for activity against
hypnozoites in primary screening for novel anti-
vivax drugs.
Sexual stages
 Development of a target product profile for a drug
to target the sexual stages of P. falciparum.
 Development of robust screening methods for stage
IV-V gametocytes of P. falciparum
 Development of a P. falciparum (and P. vivax)
ookinete assay to complement the current P berghei
assay.
 Development of male and female gamete activation
assays
 Development of MTS/HTS for SMFA assay
Identifying novel targets
There is a clear need for the identification and develop-
ment of new classes of anti-malarials, i.e. belonging to
novel chemical series and with novel modes of action.
The current reality is that much drug discovery is still
focused on a limited number of historic targets (primarily
the folate and haemoglobin degradation pathways), and
primarily on the blood stage of the parasite’s life cycle.
There is a wealth of untapped targets in the various devel-
opmental stage proteomes that might be targeted.
Databases on genes and metabolic pathways offer
opportunities to identify possible new target-based ap-
proaches. The cross-correlation of this information can
be a very valuable filter (e g, identifying genes that are
active in both gametocytes and in the blood stages).
Orthology-based screening between Plasmodium species
may also give valuable insights into promising new tar-
gets. The high level of conservation between P. falcip-
arum and P. vivax genomes indicates that novel targets
for vivax might be established from proven falciparum
targets.
As the effort against malaria moves from the control
phase to elimination, parts of the parasite life cycle be-
yond the blood stages will need to be targeted. Liver
stages, gametocytes and sporozoites were highlighted in
the Workshop as being potentially important for the
elimination phase.
Targeting erythrocytic schizogony
In the control phase, the focus is on the treatment of
symptomatic patients, i.e., treating asexual blood stages.Finding novel drug classes
One approach is the mining of genomic databases to iden-
tify novel targets (see below), followed by the screening of
high diversity chemical libraries on such targets. Another
strategy consists of first using such libraries (including
libraries of natural products) in phenotypic screens to
constitute the so-called “malaria boxes”, and subsequently
identify in secondary screens the molecular targets of
compounds with parasiticidal activity. Several million
chemical entities have been screened for anti-malarial ac-
tivity, based on whole cell screens of P. falciparum. The
screens have included fully synthetic (from both com-
mercially available and pharmaceutical industry propri-
etary sources) and natural product libraries. More
than 20,000 compounds are now available that are
known to have selective parasiticidal activity, but
whose molecular targets are unknown [50]. Many of
these are likely to act through novel pharmacophores
on novel molecular targets. A wider range of libraries
should be investigated, including compound banks
from agrochemical companies. The accompanying
paper outlines the CRIMALDDI Consortium’s recom-
mendations to expedite the use of this valuable source
of information [7].
Finding novel targets
The characteristics of a good target should include:-
“Must have” characteristics:
 Compound should be able to kill the parasite (be
“cidal”) in much less than 48 hours through either
inhibition of the target or interaction of the
compound with the target;
 The target should be validated either chemically or
genetically, both in vitro and in vivo;
 The target should be druggable, i.e. should be
amenable to treatment with small molecules at low
concentrations;
 There needs to be a reliable functional assay of the
target.
“Nice to have” characteristics:
 Lack of orthology of the target in humans;
 Cellular assay of the effect of compounds on the
target;
 A crystal structure of the target.
Considerations about the various stages in erythrocytic
schizogony
A key requirement in most target product profiles is rapid
parasite kill. The speed-of-action of the artemisinins is at-
tributed to their activity throughout the erythrocytic stage
(in contrast, most other anti-malarials that are active
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with the schizont stage and interrupting the release of
merozoites are potentially promising but unexploited
strategies.
Other processes identified for further biological under-
standing that might lead to novel targets of most value
for drug discovery were:-
 Ring stage particularly focussing on Merozoite
invasion: formation of the parasitophorous vacuole
and associated transport pathways.
 Trophozoite stage: Metabolic pathway
characterisation in the trophozoite (including
haemoglobin degradation) and host cell remodelling.
 Schizonts: Nuclear division, merozoite ontogeny,
egress mechanisms.
In the absence of robust culture systems it is reason-
able at this stage to assume P. falciparum will be a suit-
able model for blood stage P. vivax infections in many
cases. However, additional work is needed to fully valid-
ate this assumption on a hit by hit basis.Host cell targets
Recent research has identified an essential role for
host erythrocyte enzymes in parasite development
[51,52]. A number of the parasiticidal compounds
may target a host cell enzyme rather than a molecule
encoded by the parasite. Targeting host cell (erythro-
cyte or hepatocyte) enzymes that are required for
parasite survival is an additional, as yet unexploited,
therapeutic strategy. Recent research indicates that
such potential host cell targets include enzymes that
are well-established targets in other pathologies (e g,
protein kinases in cancer). A “piggy-back” approach
might be implemented that would considerably speed
up discovery/development. Additional fundamen-
tal research must be performed to validate this
approach.Targeting liver stages
The highest priority in this area is to understand the
biology of liver stage parasites, especially the hypnozoites
that act as a reservoir for P. vivax. Drug activity against
hypnozoites will become crucial during elimination. At
present even the exact definition of a hypnozoite is not
clear. Without such understanding, practical screening
techniques cannot be developed and modes of action
will be poorly understood. A high priority is to develop
simple markers to identify hypnozoites from active, in-
fected hepatocytes (preferably in human liver cells). This
would be a key step to developing screens against the
dormant stages.Priority should also be given to the following aspects
of the infected hepatocytes:
 Reactivation of hypnozoites in an in vitro model to
allow testing of compounds which block reactivation
or kill the dormant cells;
 Causes of dormancy and the reasons for liver stage
parasites to “choose” between the active and
dormant state.
Some insights or leads that may be starting points for
research were identified:-
 Known efficacy of 8-aminoquinolines (primaquine
and tafenoquine) against hypnozoites;
 The use of bio-informatics to identify potentially im-
portant genes and metabolic pathways;
 Non-haem targets in the blood stage;
 Effect of antibiotic pre-treatment of apicoplasts.
Targeting sexual development and sporogony
Gametocytes are an interesting point to interrupt trans-
mission of the parasite. This could be either the sole ac-
tivity or an additional activity from a compound that is
acting elsewhere in the life cycle. There will be some
ethical and practical issues: a purely anti-gametocyte
drug would not directly benefit the patient and so would
impose a high safety requirement on the compound. On
the other hand, a drug targeting gametocytes exclusively
(but not affecting asexual stages) would be a valuable
asset in preventing the escape of genotypes that confer
resistance against anti-asexual drugs: thus one of the
main benefits of transmission-blocking drugs would be
to protect co-administered curative drugs against resist-
ance development and spread. The mechanisms of ac-
tion of existing, blood stage, active compounds against
gametocytes should be investigated.
Recent research has identified crucial roles for several
enzymes in sexual development. Possible target processes
to attack gametocytes include:
 Gametocytogenesis: a process with many metabolic
processes active and so offering multiple points to
disrupt the parasite;
 Egress and subsequent gametogenesis mechanisms
(especially proteases, protein kinases, and lipid
metabolism);
 The mode of action of primaquine against
gametocytes and whether it has a common
biochemical target at all stages of the parasite life
cycle.
Similarly, drugs that have activity against sporozoites
might be of value. Sporozoite-active compounds would
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product profile should clarify how this type of activity
will be of demonstrable value in the field. It will be use-
ful to screen against sporozoites all the current screen-
ing hits to see if there is this additional activity to that
against blood and/or liver stages.Natural products
The chemical diversity derived from natural products is
tremendous. Natural products are an “exquisite” source
of new drugs as Nature has screened orders of magnitude
of more compounds than has been possible with HTS.
Many current anti-malarials originated as natural prod-
ucts. However in recent years no compounds in develop-
ment have originated directly from a natural product.
Many natural products have shown potent antiplasmodial
effects but have not been progressed [53]. Recent develop-
ments (such as the availability of the whole parasite
genome) warrant a re-visit of the natural product route of
drug discovery vis-à-vis target identification. Natural
products generally span a different chemical space than
synthetic compounds. In addition, natural products can be
bio-available with properties outside conventional Lipinski
space and they have evolved to interact with biological
molecules. Therefore, screening of natural products in
whole cell assays are of potentially great value in identify-
ing new druggable targets that would be rejected if the
Lipinski rules were blindly followed [54,55]. They will also
be of value in identifying polypharmacological modes of
action. The metabolic activity identified with natural prod-
ucts can also be used to define empirical targets without
initially establishing a protein target [56]. The protein/tar-
get may be determined later in the development process.
Naturally occurring “libraries” of natural products should
not be ignored, both in seeking novel chemical classes and
as tools to identify novel targets. They may have a better
chance to produce hits in drug screening because they
have evolved to interact with biological targets. Another
approach by which natural products may be useful in the
identification of druggable targets is activity-based protein
profiling [57]. Proteins/enzymes identified in this way can
then be investigated further as potential therapeutic tar-
gets by both classical mechanism of action studies or re-
verse pharmacology [58].
The shared ancestry of apicoplexans and algae suggest
that new “plant-like” targets exist beyond the apicoplast.
This may be of value in identifying leads for less meta-
bolically active stages in the parasite life cycle (e g, ga-
metocytes, hypnozoites). The problem of the regulatory
pathway with natural product mixtures was noted. The
drive for low-cost drugs also was a problem for natural
products, which are often complex molecules and have
potentially high costs of manufacture. However, bettersemi-synthetic approaches (as has is being used for arte-
misinin) may reduce this problem.Conclusion
The ambitious target of malaria elimination will only be
achieved with the development of new drugs carefully tar-
geted at the key challenges that exist for both control and
elimination. The CRIMALDDI Project aimed to identify
the most important approaches that should be adopted, as
a guide to the various organizations – policy makers, fun-
ders, and researchers – on where to prioritize their efforts.
It is clear from the recommendations of the two
Workshops described in this paper that a very pressing
need is to develop the new and improved enabling tech-
nologies that allow new drugs with the right target pro-
files to be identified quickly. These novel technologies
are often forgotten in the understandable drive towards
the development of new medicines. At a time of limited
resources, it is important that drug discovery efforts are
clearly focused on the areas of greatest need and/or
which show the greatest probability of success. Better
enabling technologies will assist in this prioritization, as
well as helping to identify novel approaches and enab-
ling them to be studied more effectively.
Exploring a more diverse range of potential drug targets
is a priority. These may be better able to address the
shortcomings of the current range of anti-malarials. A
broader approach that explores of the entire parasite’s life
cycle is recommended, as this holds the promise both of
addressing current challenges and meeting the require-
ments of drugs for elimination [29].
The work of the CRIMALDDI Project described here
and in related papers [5,7] will hopefully provide some
guidance to policy-makers, funders, and researchers in
prioritizing their malarial drug discovery efforts. It can
also draw attention to the importance of the interplay
between the existence of new technologies and the malaria
community’s ability to move beyond the current portfolio
of well-characterized and studied targets. It should add to
the global discussion on how best to prioritize scarce re-
sources, especially as the community moves into the post-
Millennium Development Goal period and an updated
Global Malaria Action Plan is being developed.Abbreviations
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